Excellent early results in large OvPlex ovarian cancer biomarker study
These data are significant as they confirm and reinforce previous findings from several smaller pilot studies and now pave the way for HealthLinx to use these markers in its OvPlex™ multimarker panel. Previous modelling with these biomarkers demonstrated improved diagnostic efficiency of the OvPlex™ panel. In combination with the other OvPlex™ biomarkers we expect a marked improvement in the diagnostic efficiency in early (Stage I-II) ovarian cancer.
“Based upon our initial studies, we always believed that AGR2 and HTX010 would boost the performance of the OvPlex™ test. These early results are certainly in line with expectations and give us great confidence that our target of achieving a test with significantly enhanced diagnostic efficiency is feasible. Our aim is to fine tune the OvPlex™ test to ultimately provide sensitivity and specificity of at least 97% in the target patient population” said Nick Gatsios, Managing Director of HealthLinx.
Further development of the diagnostic use of AGR2 is of particular relevance as Healthlinx is the exclusive licensee of intellectual property covering the use of a highly specific monoclonal antibody that forms the basis of the blood test it has developed. HealthLinx has already signed a non-exclusive license deal for the use of one anti-AGR2 monoclonal antibody for research purposes to the Millipore Corporation, one of the world’s largest research reagent companies.
Based on these data, HealthLinx will now move forward with plans to further develop and partner the AGR2 immunoassay as a clinical diagnostic tool with a range of potential applications related to cancer diagnosis and monitoring.
Most read news
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.